The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
The usefulness of dogs and monkeys in predicting potential qualitative drug toxicity in man was examined retrospectively for twenty‐five anticancer compounds of diverse chemical and functional classification. It was found that the large animal screen served to alert the physician to a significant proportion of the total spectrum of drug effects, which were encountered during the clinical use of a new toxic compound. The dog and monkey correctly predicted bone marrow depression, gastrointestinal disturbance, and hepatotoxicity for each drug producing these effects in the clinic; in the case of renal, cardiovascular, and neuromuscular toxicity, however, the large animal screen failed in each instance to predict one drug that produced these toxicities in man. The correct predictions were accomplished at the expense of a high percentage of false positives, which resulted from the necessity of using severely toxic dose levels in order to demonstrate all potential toxicities inherent in any compound. While organ system toxicity observed during an animal study can never be disregarded, it should be viewed with an understanding of certain limitations of animal toxicologic data. While toxicity may develop in man in an organ system predicted susceptible by an animal, a different specific clinical or chemical parameter may be involved. The adverse reaction may appear in man at a greater or lesser dose level or may follow a different order of appearance in relationship to the total spectrum of qualitative toxicity inherent in the compound.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, Schein present an analysis of 25 anticancer drug toxicities in several papers [83–86], each paper combining the analysis with other information.”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [86]
Citations
Cites
Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., & Skipper, H. E. (1966) · PubMed · Cited by 1,382
Self-citationMitomycins and Porfiromycin: Chemical Mechanism of Activation and Cross-linking of DNA
Iyer, V. N., & Szybalski, W. (1964) · Science · doi:10.1126/science.145.3627.55 · Cited by 570
Tan, C., Tasaka, H., Yu, K.-P., Murphy, M. L., & Karnofsky, D. A. (1967) · Cancer · doi:10.1002/1097-0142(1967)20:3<333::aid-cncr2820200302>3.0.co;2-k · Cited by 486
Studies on the Diabetogenic Action of Streptozotocin (NSC37917)
Raikieten, N. (1963) · Medical Entomology and Zoology · Cited by 443
The use of body surface area as a criterion of drug dosage in cancer chemotherapy.
Pinkel, D. P. (1958) · PubMed · Cited by 344
Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962.
Vt, D. V., Pp, C., Owens, A. H., Gold, G. L., Mj, K., & Edmonson, J. H. (1965) · PubMed · Cited by 218
Clinical studies with 5-fluorouracil.
Curreri, A. R., Ansfield, F. J., McIver, F. A., Waisman, H. A., & Heidelberger, C. (1958) · PubMed · Cited by 206
Schein, P. S., Cooney, D. A., & Vernon, M. L. (1967) · PubMed · Cited by 206
Self-citationComparative patterns of drug metabolism.
Williams, R. T. (1967) · PubMed · Cited by 170
A Syllabus of Laboratory Examinations in Clinical Diagnosis
Perry, C. A., Humphrey, J., & Brownlee, M. (1951) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.41.8_pt_1.1010-a · Cited by 159
Cited by
Items 101–147 of 147
Creaven, P. J., & Kanter, P. M. (1987) · Springer eBooks · doi:10.1007/978-1-4613-2317-4_7 · Cited by 4
Greaves, P. (2007) · Elsevier eBooks · doi:10.1016/b978-044452771-4/50009-2 · Cited by 5
Kornbrust, D. J. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0781 · Cited by 3
“Resulting publications demonstrated that direct extrapolation from the body weight-relative maximum tolerated dose (MTD) underpredicted human sensitivity, and that better correlation of MTDs across species was obtained by expressing doses per BSA [4,5].”
Animal Models in Toxicologic Research: Dog
Foster, J. R., Mowat, V., Singh, B., Ingram–Ross, J. L., & Bradley, D. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821044-4.00008-x · Cited by 9
Arguments Against Using Nonhuman Primates in Research
Bailey, J. (2023) · Springer eBooks · doi:10.1007/978-3-030-82708-3_23 · Cited by 4
Bode, G., Starck-Lantova, P., & Kramer, P.-J. (2023) · Springer eBooks · doi:10.1007/978-3-030-73317-9_142-1 · Cited by 4
Detecting functional neurotoxicity in the course of safety evaluations with laboratory animals
Schaeppi, U. H. (1988) · Toxicology · doi:10.1016/0300-483x(88)90026-1 · Cited by 3
Beagle dog as predictor of schedule-dependent toxicity of 5-fluoro-2-deoxyuridine
Henry, M. C., Blair, W. H., Shefner, A. M., & Schein, P. (1972) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(72)90056-7 · Cited by 3
Self-citationThe Scientific Value of Non-Clinical Animal Studies in Drug Development
van Meer, P. J. K. (2013) · Utrecht University Repository (Utrecht University) · Cited by 8
Bailey, J. (2014) · Alternatives to Laboratory Animals · doi:10.1177/026119291404200208 · Cited by 3
Data Processing and Interpretation
(2009) · CRC Press eBooks · doi:10.1201/9781420080124.ch14 · Cited by 3
THERAPEUTIC RESEARCH IN THE NATIONAL CANCER INSTITUTE
DeVita, V. T., & Goidin, A. (1984) · Elsevier eBooks · doi:10.1016/b978-0-12-667980-9.50032-4 · Cited by 2
Estimation of Human Starting Dose for Phase I Clinical Programs
Buckley, L. A., Garhyan, P., Ponce, R. A., & Roberts, S. (2010) · Wiley eBooks · doi:10.1002/9780470613191.ch10 · Cited by 2
Current therapy approaches of the division of cancer treatment with emphasis on pancreatic carcinoma
Carter, S. K. (1974) · Journal of Surgical Oncology · doi:10.1002/jso.2930060103 · Cited by 2
“this practice is supported by both qualitative and quantitative studies (Schein et al., 1970; Dedrick et al., 1970).”
MethodSelf-citationGreaves, P. (2000) · Elsevier eBooks · doi:10.1016/b978-044450514-9/50007-3 · Cited by 2
Risk Assessment of Genotoxic Carcinogens
Zeise, L. A. (2001) · doi:10.1201/9780203904237-16 · Cited by 2
Chance and Choice in the Discovery of Drugs
Weatherall, M. (1972) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591577206500406 · Cited by 2
“Animals are fair, but not infallible, predictors of what will happen in man (Paget 1962, Welch 1967, Schein et al. 1970).”
BackgroundRegulatory Toxicological Studies: Identifying Drug-Induced Liver Injury Using Nonclinical Studies
Hausner, E. A., & Khan, I. M. (2018) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-7677-5_19 · Cited by 1
Telemetry in Nonclinical Drug Safety Assessment Studies
Gad, S. C., & Gad, S. C. (2015) · CRC Press eBooks · doi:10.1201/b18705-17 · Cited by 1
Murazov, Y. G., Нюганен, А. О., & Artemyeva, A. S. (2021) · Voprosy Pitaniya · doi:10.33029/0042-8833-2021-90-3-104-115 · Cited by 1
Future of Regulatory Safety Assessments
Bode, G., & Starck-Lantova, P. (2020) · Springer eBooks · doi:10.1007/978-3-319-68864-0_71 · Cited by 1
Mishra, A., Mishra, P., Tekade, M., Gupta, R., Rajpoot, K., Mohamed, F., & Tekade, R. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15840-7.00020-8 · Cited by 2
Olson, H. M., & Davies, T. S. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511779053.003 · Cited by 1
Backes, K., Lorenz, H., Laplanche, L., Hudzik, T. J., Potschka, H., & Hempel, K. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.12.007 · Cited by 1
A Chemotherapeutic Perspective on Clinical Trials with Corynebacterium parvum
Carter, S. K., & Slavik, M. (1975) · Springer eBooks · doi:10.1007/978-1-4613-4428-5_37 · Cited by 1
Self-citationAssessments of New Methods of Cancer Therapy
Baker, C. G. (1970) · Postgraduate Medicine · doi:10.1080/00325481.1970.11693597 · Cited by 1
Assessment of the Toxicity of Antiinflammatory Drugs
Lévy, L. (1974) · Elsevier eBooks · doi:10.1016/b978-0-12-623902-7.50011-6 · Cited by 1
Prinzipien der Zytostatika-Testung
Klein, H. (1977) · Annals of Hematology · doi:10.1007/bf00996289 · Cited by 1
Risk Assessment of Genotoxic Carcinogens
Zeise, L. A. (2001) · Informa Healthcare eBooks · doi:10.1201/9780203904237.ch14 · Cited by 1
Agent-Directed Preclinical Toxicology for New Antinfoplastic Drugs
Grieshaber, C. K. (1992) · Springer eBooks · doi:10.1007/978-1-4615-3492-1_15
GOLDIN, A. S., & Schein, P. S. (1984) · Springer eBooks · doi:10.1007/978-1-4613-3837-6_29
Self-citationPrinzipien der Zytostatika-Testung
Klein, H. O. (1977) · Annals of Hematology · doi:10.1007/bf00996633
Manca, D., Walker, R. M., Krishna, G., Graziano, M. J., & Kropko, M. L. (1999) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.1998.1275
Contributions of Pharmacologic Studies of Anticancer Drugs to Their Clinical Trials
Loo, T. L. (1985) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.16.307
Toxicokinetics: An Integral Component of Preclinical Toxicity Studies
Singh, S. S. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse082
Chemotherapy from Animals to Man
Ohnuma, T., & Holland, J. F. (1989) · Springer eBooks · doi:10.1007/978-94-009-1089-8_17
Carter, S. K. (1974) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-80848-7_2
Self-citationAnimal Tests as Predictors of Human Response
Folb, P. I. (1990) · doi:10.1007/978-1-349-10705-6_5
Foo, S. C., Ivan, S.-M. S., Hui-Fang, A., & Rachel, Q.-Y. C. (2017) · Journal of Biophysics and Structural Biology · doi:10.5897/ajbr2016.0057
“This principle was first confirmed empirically with toxicity data of 18 anticancer drugs by Freireich et al. (1966) and evaluated further by Schein et al. (1970).”
BackgroundFuture of Regulatory Safety Assessments
Bode, G., & Starck-Lantova, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-56637-5_71-1
Future of Regulatory Safety Assessments
Bode, G., & Starck-Lantova, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-56637-5_71-2
Risk Assessment and Low- Dose Extrapolation
(2005) · CRC Press eBooks · doi:10.1201/b14252-17
A Pseudoscience Tale: Insufficient Evidence Regarding Chlorine Dioxide’s Toxicity and Efficacy
Pastrana, L. I. C., Rico-Cuevas, J. I., Martínez-Hernández, L., Lozano-Jiménez, I., Dreser, A., & Hegewisch-Taylor, J. (2023) · Latin American Journal of Clinical Sciences and Medical Technology · doi:10.34141/ljcs8201440
Bode, G., Starck-Lantova, P., & Kramer, P.-J. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_142
抗癌剤のトキシコキネティックス・トキシコダイナミックス : ヒトにおける抗癌剤の最大耐用量(MTD)の予測とpharmacokinetically guided dose escalation法
布施英一, 稲葉, 實., & Sugiyama, Y. (1993) · The Journal of Toxicological Sciences · doi:10.2131/jts.18.4_app4
Die pharmakologischen Grundlagen der Behandlung der Leukämien
Obrecht, J. P. (1973) · Verhandlungen der Deutschen Gesellschaft für Innere Medizin · doi:10.1007/978-3-642-47087-5_43
Metadata
- Authors
- Schein, P. S., Davis, R. D., Carter, S., Newman, J., Schein, D. R., & Rall, D. P.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Newman, J.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1970-01
- Volume
- 11
- Issue
- 1
- Pages
- 3-40
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2415622130
- Cited by
- 146
- References
- 53
- Citations by year
- 2024: 1 · 2023: 5 · 2022: 1 · 2021: 3 · 2020: 5 · 2019: 2 · 2018: 4 · 2017: 4 · 2016: 3 · 2015: 6 · 2014: 5 · 2013: 4 · 2012: 5
- FWCI
- 16.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Health Sciences › Veterinary › Small Animals › Veterinary Oncology Research
- Keywords
- anticancer agents, drug toxicity prediction, dogs, monkeys, bone marrow depression, hepatotoxicity, gastrointestinal toxicity, nephrotoxicity, cardiotoxicity, neuromuscular toxicity, false positives, animal-to-human extrapolation, adverse drug reactions
- MeSH terms
- Animals, Haplorhini, Antimetabolites, Antineoplastic Agents, Bone Marrow Diseases, Cardiovascular Diseases, Dogs, Eye Manifestations, Gastrointestinal Diseases, Humans, Kidney Diseases, Lymphatic Diseases, Lymphopenia, Methods, Neurologic Manifestations, Respiratory Tract Diseases, Skin Manifestations, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.